First-in-class, anti-cancer mitochondrial drug found to be effective against most carcinoma cell lines
A study of the lead agent (CPI-613) in a class of anticancer drugs undergoing Food and Drug Administration (FDA) approved clinical trials reveals that CPI-613 is effective against most carcinoma cell lines, and, used in combination, could have efficacy against reducing some tumors.
Source: news-medical.net